The University of Iowa has entered into a development agreement with Moleculin, for its breakthrough cancer treatment molecule, WP1732
Moleculin Biotech, a clinical stage pharmaceutical company focused on the development of oncology drug candidates, all of which are based on license agreements with The University of Texas System, on behalf of the MD Anderson Cancer Center, has entered into an agreement with The University of Iowa Pharmaceuticals for the development of a formulation for WP1732.
“WP1732, which we believe, based on preclinical testing, is a breakthrough discovery, is now advancing to the stage of formulation development,” commented Walter Klemp, Moleculin’s Chairman and CEO.
“With the demand for clinical testing of WP1066 continuing to grow, it is easy to forget that we believe WP1732 represents a major expansion of our STAT3 inhibition capability by providing a highly soluble alternative that is ideally suited for IV administration.”
“This agreement marks the beginning of our creating a preclinical package to submit to the FDA to request investigational new drug status.”